Janssen Gives New Lease of Life to Geron by Agreeing to License its Sole Pipeline Asset
By Heather Cartwright
Pharma Deals Review: Vol 2014 Issue 11 (Table of Contents)
Published: 26 Nov-2014
DOI: 10.3833/pdr.v2014.i11.2078 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Only 10 days after the US FDA removed a clinical hold on its sole pipeline asset imetelstat, Geron has partnered with Johnson & Johnson’s JanssenBiotech for the development and commercialisation of the telomerase inhibitor in a deal that could be worth uptoUS$935 M...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS